TransMedics Group (TMDX) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of TransMedics Group (NASDAQ: TMDX) in the last few weeks:

• 3/16/2026 – TransMedics Group had its “buy” rating reaffirmed by TD Cowen.
• 3/9/2026 – TransMedics Group had its price target raised by Stifel Nicolaus from $115.00 to $130.00. They now have a “hold” rating on the stock.
• 2/28/2026 – TransMedics Group was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/25/2026 – TransMedics Group had its price target raised by Oppenheimer Holdings, Inc. from $150.00 to $175.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – TransMedics Group had its price target raised by JPMorgan Chase & Co. from $114.00 to $149.00. They now have a “neutral” rating on the stock.
• 2/25/2026 – TransMedics Group had its price target raised by Piper Sandler from $140.00 to $160.00. They now have an “overweight” rating on the stock.
• 2/25/2026 – TransMedics Group had its price target raised by Needham & Company LLC from $166.00 to $174.00. They now have a “buy” rating on the stock.
• 2/14/2026 – TransMedics Group was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/31/2026 – TransMedics Group was downgraded by Wall Street Zen from “buy” to “hold”.

Insiders Place Their Bets

In other news, CFO Gerardo Hernandez sold 7,236 shares of TransMedics Group stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total value of $1,065,211.56. Following the completion of the transaction, the chief financial officer directly owned 14,689 shares of the company’s stock, valued at approximately $2,162,367.69. The trade was a 33.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Nicholas Corcoran sold 2,966 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $412,629.92. Following the sale, the insider owned 29,831 shares in the company, valued at approximately $4,150,088.72. This trade represents a 9.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 16,205 shares of company stock worth $2,353,002. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.